Why the study?
Drug-coated balloon angioplasty has suboptimal efficacy in long and calcified femoropopliteal lesions, and whether adding atherectomy confers a durable patency and target lesion revascularization benefit in long lesions remained unclear.
Population
Eleven studies of patients with long femoropopliteal lesions
Comparison
Atherectomy plus drug-coated balloon vs drug-coated balloon alone
Design
Random-effects meta-analysis
Follow-up
12 and 24 months
Answers are grounded in this paper and cite their sources.
Meta-analysis shows adding atherectomy to drug-coated balloons improves 12-month patency and reduces bailout stenting in long femoropopliteal lesions, suggesting benefits attenuate by two years.
Background: Drug-coated balloon (DCB) angioplasty is widely used to treat femoropopliteal (FP) lesions, yet its efficacy in long and calcified lesions remains suboptimal. Recent vessel preparation data indicate that atherectomy (AT) reduces bailout stenting in shorter lesions, but its benefit in terms of target lesion revascularization (TLR) remains unclear. Whether adding AT to DCB confers a durable patency benefit in long lesions remains unclear. The present pooled analysis therefore focuses on mid-term outcomes in long lesions. Materials and methods: We searched major databases for studies comparing AT plus DCB with DCB alone. The primary outcome was the 12-month patency-related outcome. Secondary endpoints included the 24-month patency-related outcome, TLR/clinically driven TLR (CD-TLR) at both time points, and bailout stenting. Lesion-length subgroups were also explored. Risk ratios (RRs) were pooled using a random-effects model. Risk of bias and evidence quality were assessed using standard tools. Results: Eleven studies were included. Compared with DCB alone, AT plus DCB was associated with a higher rate of 12-month patency-related outcomes [RR = 1.14, 95% confidence interval (CI) 1.01–1.29, P = 0.04; I 2 = 78%] and a lower risk of bailout stenting (RR = 0.41, 95% CI: 0.24–0.69, P = 0.0009; I 2 = 23%). At 24 months, patency numerically favored the combined strategy but was not statistically significant. 12- and 24-month TLR/CD-TLR did not differ significantly; sensitivity analyses indicated that these null findings were substantially influenced by one cohort (Cha et al ). Lesion-length subgroup analysis showed no clear treatment-effect difference. Clinical-presentation subgroup analysis was not feasible because stratified treatment-effect data were unavailable. Conclusion: AT before DCB was associated with improved 12-month patency-related outcomes and reduced bailout stenting in long FP lesions. This advantage appears time-dependent and attenuates by 24 months. Taken together, AT should be reserved as a selective strategy for long, complex, and calcified lesions rather than used routinely. Large-scale randomized trials with longer follow-up are warranted.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: